On Thursday, the U.S. Food and Drug Administration (FDA) approved Guardant Health Inc.’s (NASDAQ:GH) Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with Braftovi (encorafenib) in combination with cetuximab and chemotherapy.The accelerated approval for Braftovi was supported by data from Pfizer Inc.’s (NYSE:PFE) Phase 3 BREAKWATER trial.DataThe study showed that treatment with encorafenib and cetuximab p ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck's oncology portfolio using the Guardant Infinityâ"¢ Smart platform. Use Guardant's portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck's global clinical studies, Evaluate opportunities to develop novel ...